Article info
PDFBasic and translational research
Extended report
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
- Correspondence to Dr Nadira Ruzehaji, Institut Cochin, INSERM U1016, Bâtiment Gustave Roussy, 27 rue du Faubourg Saint Jacques Paris, 75014, France; nadira.ruzehaji{at}inserm.fr
Citation
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
Publication history
- Received June 4, 2015
- Revised February 3, 2016
- Accepted February 21, 2016
- First published March 9, 2016.
Online issue publication
November 10, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/